Search

Displaying results 8191 - 8200 of 8415 in total
  1. Drug

    Nesolicaftor

    go.drugbank.com/drugs/DB15239
    Investigational

    Nesolicaftor (PTI-428) is under investigation in clinical trial NCT03258424 (Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background

  2. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. … The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.

  3. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats. … Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well

  4. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  5. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractiv...

  6. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...

  7. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

  8. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease

  9. Drug

    Fiztasovimab

    go.drugbank.com/drugs/DB24033
    Investigational

    Fiztasovimab, also known as NPC‐21 and EV2038, is a monoclonal antibody.

  10. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common